ArticleNeurourology and urodynamics2021
Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence.
Article in Neurourology and urodynamics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Urethral Bulking Agent as a Salvage Procedure for Female Stress Urinary Incontinence: A Systematic Review and Meta-Analysis.International urogynecology journal · 2025Pooled it
- Efficacy and safety of electrical stimulation for stress urinary incontinence in women: a systematic review and meta-analysis.International urogynecology journal · 2022Pooled it
- A prospective, open-label, clinical investigation of a single intra-articular polyacrylamide hydrogel injection in participants with knee osteoarthritis: a 5-year extension study.Journal of orthopaedic surgery and research · 2025Trial
- Hydrogel-Based Therapies for Female Stress Urinary Incontinence: From Bulking Agents to Regenerative Platforms-A Narrative Review.Current urology reports · 2026Review
- Effect of intrinsic sphincter deficiency on treatment success following urethral bulking with polyacrylamide hydrogel.Investigative and clinical urology · 2026Article
- Symptom Relief and Practice Setting Variation in Bulkamid Injections for Stress Urinary Incontinence.Neurourology and urodynamics · 2026Article
- Changes in Urgency Urinary Incontinence Symptoms After Stress Urinary Incontinence Surgery in Women.International urogynecology journal · 2026Article
- Failure Rate, Time to Failure, and Associated Risk Factors: Polyacrylamide Hydrogel Injection for the Treatment of Stress Urinary Incontinence in a Large Cohort.International urogynecology journal · 2026Article
- Submucosal urethral bulking with 2.5% polyacrylamide hydrogel (Mictamid) for urinary incontinence in male dogs using a percutaneous fluoroscopically assisted perineal approach.Journal of veterinary internal medicine · 2026Article
- Intraurethral cross-linked hyaluronic acid/dextranomer (DEXSUI®) injection versus mid-urethral sling for stress urinary incontinence: a comparative short-term outcome analysis.The Canadian journal of urology · 2026Article
- Functional hydrogel biomaterials for urological diagnosis and treatment-design strategies and application progress: a review.Journal of materials science. Materials in medicine · 2026Review
- The Impact of Treatment Setting on Periurethral Bulking.International urogynecology journal · 2026Article
- Stress Urinary Incontinence Procedure Outcomes in the < 40-Year-Old Population: A Multicenter Study.International urogynecology journal · 2026Article
- Improved healing and tissue regeneration for prevention and treatment of pelvic floor disorders: from reactive treatment to proactive prevention.Frontiers in bioengineering and biotechnology · 2026Review
- Modern Conservative Management Strategies for Female Stress Urinary Incontinence: A Systematic Review.Journal of clinical medicine · 2025Review
- Article
- Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Bulking Agent for Stress Urinary Incontinence: Patient Choice and Outcomes in Finland.International urogynecology journal · 2025Article
- An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCellFrontiers in toxicology · 2025Article
- Effectiveness and Safety Profile of Urethral Bulking with BulkamidInternational urogynecology journal · 2025Article
- Hydrogels in the clinic: An update.Bioengineering & translational medicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsBulking agents are a minimally invasive treatment option for women with stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI). The aim of this study was to evaluate long-term efficacy and safety following treatment with Bulkamid as a primary procedure for SUI or stress-predominant MUI.
methodsThis was an Institutional Review Board-approved single-center retrospective study of female patients with SUI or stress-predominant MUI who had undergone injection with Bulkamid since 2005 and had completed 7 years of follow up. The primary endpoint was patient satisfaction measured on a four-point scale as cured, improved, unchanged, or worse. Secondary outcomes included the number of incontinence pads used, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-UI SF) scores, Visual Analog Scale Quality of Life (VAS QoL), reinjection rates, and perioperative and postoperative complications.
resultsA total of 1,200 patients were treated with Bulkamid since 2005 and of these, 388 (32.3%) had completed 7 years of follow-up. A total of 67.1% of the patients reported feeling cured or improved if Bulkamid was a primary procedure, 11.1% reported no change, and 2.3% reported worsening of incontinence. A total of 19.5% of patients received a subsequent other incontinence procedure. The ICIQ-UI SF was reduced by 8.6 points. VAS QoL improved by a mean of 4.3 points. Postoperative complications were transient. Prolonged bladder emptying time was reported in 15.3% of patients and urinary tract infection in 3.5%.
conclusionsBulkamid injections are an effective and safe first-line treatment option for women with SUI or stress-predominant MUI providing durable outcomes at 7 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.